替考拉宁治疗慢性阻塞性肺疾病合并革兰阳性球菌感染患者的临床效果  

Teicoplanin in treatment of COPD complicated with gram-positive cocci infections

作　　者：郑学明[1] 张爱云[1] 

机构地区：[1]山东省寿光市人民医院药剂科,262700

出　　处：《国际医药卫生导报》2016年第16期2496-2499,共4页International Medicine and Health Guidance News

摘　　要：目的探讨替考拉宁（Teicoplanin，TCL）治疗慢性阻塞性肺疾病（COPD）合并革兰阳性球菌（GPC）感染患者的临床效果。方法选择2012年5月至2014年1月于本院诊治的COPD合并GPC感染患者80例，随机将其分为观察组（TCL治疗）和对照组[万古霉素（Vancomvcin，VCM）治疗1，各40例。记录两组临床疗效、细菌学疗效和不良反应发生情况。结果观察组有效率85．0％，明显高于对照组65．0％（P〈0．05）。TCL治疗后，52株GPC中，40株被清除或部分清除，清除率为76．9％；VCM治疗后，44株GPC中，28株被清除或部分清除，清除率为63．6％；两组差异无统计学意义（P〉0．05）。观察组不良反应发生率12．5％，显著低于对照组的32．5％（P〈0．05）。结论使用TCL治疗COPD合并GPC感染的患者较VCM具有更好的临床效果，GPC清除率更高，且毒副反应小，造成的不良反应更小。Objective To explore the effect of teicoplanin in the treatment of COPD complicated with gram-positive cocci （GPC） infections. Methods 80 patients with COPD complicated with GPC infection treated at our hospital from May, 2012 to January, 2014 were selected and were randomly divided into an observation group （accepted teicoplanin therapy） and a control group （received vancomycin therapy）, 40 cases for each group. The clinical efficacy, bacteriological efficacy, and adverse events of these two groups were recorded. Results The clinical efficacy was 85.0% in the observation group and 65.0% in the control group, with a statistical difference （P〈0.05）. 40 of 52 GPC has been cleared or partially cleared by using teicoplanin, the clearance rate was 76.9%; and 28 of 44 GPC has been cleared or partially cleared by using vancomycin, the clearance rate was 63.6%; the difference was not significant （P〉0.05）. The incidence of adverse reactions was 12.5% in the observation group and 32.5% in the control group（P〈0.05）. Conclusions Teicoplanin for patients with COPD complicated with GPC infection has better clinical efficacy, higher clearance rate of GPC, less toxicity, and less side effects than vancomycin.

关 键 词：替考拉宁 革兰阳性球菌 慢性阻塞性肺疾病 

分 类 号：R563[医药卫生—呼吸系统]